2023 ESMO：四大癌症领域关键研究题目速览

2023年欧洲肿瘤内科学会（ESMO）年会将于当地时间10月20日至24日在西班牙马德里召开。本文将为读者提供肺癌、乳腺癌、消化系统肿瘤和妇科肿瘤药物治疗领域的重点研究内容摘要，以供速览。

Durvalumab (durva) after sequential chemoradiotherapy (CRT) in patients (pts) with unresectable Stage III NSCLC: Final analysis from PACIFIC-6

无法切除的III期NSCLC患者在序贯放化疗（CRT）后使用度伐利尤单抗（durva）：来自PACIFIC-6的最终分析

SAPPHIRE: Phase 3 Study of Sitravatinib Plus Nivolumab Versus Docetaxel in Patients With Previously Treated Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

SAPPHIRE:Sitravatinib联合纳武利尤单抗对比多西他赛治疗经治晚期非鳞状非小细胞肺癌（NSCLC）的III期研究

Overall Survival from a Phase II Randomised Double-Blind Trial (PERLA) of Dostarlimab (dostar) + Chemotherapy (CT) vs Pembrolizumab (pembro) + CT in Metastatic Non-Squamous NSCLC

在转移性非鳞状NSCLC中，Dostarlimab (dostar) +化疗（CT）对比帕博利珠单抗（Pembro）+ CT的II期随机双盲试验（PERLA）的总生存率

KRYSTAL-7: Efficacy and safety of adagrasib with pembrolizumab in patients with treatment-naïve, advanced non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation

KRYSTAL-7:adagrasib联合帕博利珠单抗一线治疗KRAS G12C突变的晚期非小细胞肺癌（NSCLC）患者的疗效和安全性

FLAURA2: safety and CNS outcomes of first-line (1L) osimertinib (osi) ± chemotherapy (CTx) in EGFRm advanced NSCLC

FLAURA2：一线奥希替尼±化疗治疗EGFR突变晚期NSCLC的安全性和中枢神经系统结果

OSIRAM-1: A multicenter, open label, randomized phase II study of osimertinib plus ramucirumab versus osimertinib alone as initial chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer (TORG1833)

OSIRAM-1：一项多中心、开放标签、随机II期研究，将奥希替尼联合雷莫西尤单抗对比奥希替尼作为EGFR突变阳性非鳞状非小细胞肺癌的初始化疗（TORG1833）

A Multi-Centre Open-Label Randomized Phase II Study of Osimertinib with and without Ramucirumab in TKI-naïve EGFR-mutant Metastatic NSCLC (RAMOSE trial interim analysis)

一项多中心开放标签随机II期研究：奥希替尼联合和不联合雷莫西尤单抗初始治疗EGFR突变的转移性NSCLC （RAMOSE试验中期分析）

Neoadjuvant nivolumab (N) + chemotherapy (C) in the phase 3 CheckMate 816 study: 3-y results by tumor PD-L1 expression

CheckMate 816 Ⅲ期研究中的新辅助纳武利尤单抗（N）+化疗（C）：PD-L1表达肿瘤的3年结果

Combining the antigen-presenting cell activator eftilagimod alpha (soluble LAG-3) and pembrolizumab: overall survival data from the 1st line non-small cell lung carcinoma (NSCLC) cohort of TACTI-002 (Phase II)

结合抗原呈递细胞激活剂eftilagimod alpha（可溶性LAG-3）和pembrolizumab：来自TACTI-002（II期）研究一线治疗NSCLC队列的OS数据

Neoadjuvant nivolumab (N) + ipilimumab (I) vs chemotherapy (C) in the phase 3 CheckMate 816 trial

Ⅲ期CheckMate 816：新辅助纳武利尤单抗（N）+伊匹木单抗（I）vs 化疗（C）

TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)

TROPION-Lung05：datopotamab deruxtecan（Dato-DXd）治疗既往经治的具有可靶向基因组改变（AGA）的NSCLC

Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)

HER2×HER3双特异性抗体zenocutuzumab在晚期NRG1融合阳性（NRG1+）非小细胞肺癌 ( NSCLC )中的持久疗效

Trastuzumab Deruxtecan (T-DXd) in Patients (pts) With HER2 (ERBB2)-Mutant (HER2m) Metastatic Non–Small Cell Lung Cancer (NSCLC) With and Without Brain Metastases (BMs): Pooled Analyses From DESTINY-Lung01 and DESTINY-Lung02

DESTINY-Lung01和DESTINY-Lung02汇总分析：德曲妥珠单抗（T-DXd）治疗HER2（ERBB2）突变（HER2m）伴/不伴脑转移（BM）的转移性NSCLC

Intracranial efficacy of HER3-DXd in patients with previously treated advanced EGFR-mutated NSCLC: results from HERTHENA-Lung01

HERTHENA-Lung01：HER3-DXd治疗既往经治的晚期EGFR突变NSCLC的颅内活性

Updated study results of pelcitoclax (APG-1252) combined with osimertinib in patients (pts) with EGFR-mutant non-small cell lung cancer (NSCLC)

pelcitoclax（APG-1252）联合奥希替尼治疗EGFR突变型非小细胞肺癌（NSCLC）患者(pts)的最新研究结果

Impact of body mass index and its change on survival outcomes in patients with early breast cancer: a pooled analysis of individual-level data from BCIRG-001 and BCIRG-005 trials

体重指数及其变化对早期乳腺癌患者生存结果的影响：基于BCIRG-001和BCIRG-005试验的个体水平数据的汇总分析

Longterm residential and workplace exposure to air pollution and breast cancer risk: a case-control study nested in the French E3N cohort from 1990 to 2011

长期居住和工作环境对空气污染的暴露与乳腺癌风险：一项嵌套在法国E3N队列研究中的病例对照研究，时间跨度为1990年至2011年

Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase 3 DESTINY-Breast04 study

随机、Ⅲ期DESTINY-Breast04研究更新的生存结果：德曲妥珠单抗 vs 医生选择的治疗 (TPC) 治疗HER2低表达不可切除和/或转移性乳腺癌患者

A Pooled Analysis of Trastuzumab Deruxtecan (T-DXd) in Patients (pts) With HER2-Positive (HER2+) Metastatic Breast Cancer (mBC) With Brain Metastases (BMs) from DESTINY-Breast (DB) -01, -02, and -03

DESTINY-Breast (DB) -01、DB-02和DB-03研究的汇总分析：德曲妥珠单抗治疗伴脑转移的HER2阳性转移性乳腺癌患者

Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): updated results from BEGONIA, a phase 1b/2 study

1b/Ⅱ期BEGONIA研究的更新结果：Dato-DXd+度伐利尤单抗一线治疗不可切除局部晚期/转移性三阴性乳腺癌患者

Updated results from the phase 1/2 study of OP-1250, an oral complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD ) in patients (pts) with advanced or metastatic ER-positive, HER2-negative breast cancer.

OP-1250，一种口服的完全雌激素受体（ER）拮抗剂（CERAN）和选择性ER降解剂（SERD）在晚期或转移性ER阳性、HER2阴性乳腺癌患者（pts）中的1/2期研究的更新结果

Imlunestrant with or without everolimus or alpelisib, in ER+, HER2- advanced breast cancer (aBC): Results from the phase 1a/b EMBER study

Imlunestrant联合依维莫司或阿帕替利栓，用于ER+、HER2-晚期乳腺癌（aBC）：来自1a/b期EMBER研究的结果

Final overall survival analysis for fulvestrant vs anastrozole in endocrine therapy (ET)-naïve, hormone receptor-positive (HR+) advanced breast cancer (FALCON)

氟维司群与阿那曲唑在未经内分泌治疗 (ET) 的激素受体阳性 (HR+) 晚期乳腺癌 (FALCON) 中的最终总体生存分析

Pembrolizumab plus Trastuzumab and Chemotherapy for HER2+ Metastatic Gastric or Gastroesophageal Junction (mG/GEJ) Adenocarcinoma: Survival results from the Phase 3, Randomized, Double-blind, Placebo-controlled KEYNOTE-811 Study

Ⅲ期、随机、双盲、安慰剂对照KEYNOTE-811研究的生存结果：帕博利珠单抗+曲妥珠单抗+化疗治疗HER2+转移性胃或食管胃交界部（mG/GEJ）腺癌 

Perioperative camrelizumab (C) combined with rivoceranib (R) and chemotherapy (chemo) versus chemo for locally advanced resectable gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: the first interim analysis of a randomized, phase 3 trial (DRAGON IV)

随机、Ⅲ期试验（DRAGON IV）的首次期中分析：围术期卡瑞利珠单抗（C）+ rivoceranib（R）+化疗（chemo） vs. chemo治疗局部晚期可切除胃或食管胃交界部（G/GEJ）腺癌

A Phase II study of Nivolumab plus low dose Ipilimumab as 1st line therapy in patients with advanced gastric or esophago-gastric junction MSI-H tumor: First results of the NO LIMIT study (WJOG13320G/CA209-7W7)

Nivolumab联合低剂量Ipilimumab一线治疗晚期胃或食管胃结合部MSI-H肿瘤患者的II期研究:NO LIMIT研究的初步结果(WJOG13320G/CA209-7W7)

Nab-paclitaxel plus gemcitabine versus modified FOLFIRINOX or S-IROX in metastatic or recurrent pancreatic cancer (JCOG1611, GENERATE): a multicenter, randomized, open-label, three-arm, phase 2/3 trial

多中心、随机、开放、三臂、Ⅱ/Ⅲ期研究（JCOG1611, GENERATE）：白蛋白结合型紫杉醇+吉西他滨 vs. mFOLFIRINOX或S-IROX治疗转移性或复发性胰腺癌

AdvanTIG-206: Phase 2 Randomized Open-Label Study of Ociperlimab (OCI) + Tislelizumab (TIS) + BAT1706 (Bevacizumab Biosimilar) Versus TIS + BAT1706 in Patients (pts) With Advanced Hepatocellular Carcinoma (HCC)

AdvanTIG-206：Ociperlimab（OCI）+替雷利珠单抗（TIS）+BAT1706（贝伐珠单抗生物类似物）vs TIS + BAT1706治疗晚期肝细胞癌（HCC）患者（pts） 的Ⅱ期随机开放标签研究

Advanced extrahepatic cholangiocarcinoma: post-hoc analysis of the ABC-01, -02 and -03 clinical trials

晚期肝外胆管癌：ABC-01、-02和-03临床试验的事后分析

Tinengotinib in Patients with Advanced, Fibroblast Growth Factor Receptor (FGFR) inhibitor Refractory/Relapsed Cholangiocarcinoma

tinengotinib用于治疗晚期成纤维细胞生长因子受体 (FGFR) 抑制剂难治性/复发性胆管癌患者

Safety and efficacy of D-1553 in combination with cetuximab in KRAS G12C mutated colorectal cancer (CRC): a phase II study

D-1553联合西妥昔单抗治疗KRAS G12C突变结直肠癌（CRC）安全性和有效性的II期研究

Cetuximab Plus FOLFOXIRI Versus Cetuximab Plus FOLFOX as conversion therapy in RAS Wild-type Patients with Initially Unresectable Colorectal Liver
西妥昔单抗加FOLFOXIRI vs.西妥昔单抗加FOLFOX作为RAS野生型初始不可切除结直肠肝患者的转化疗法

A phase II clinical trial of sintilimab plus chidamide combined with or without bevacizumab in patients with MSS/pMMR metastatic colorectal cancer
信迪利单抗加西达本胺联合或不联合贝伐珠单抗治疗MSS/pMMR转移性结直肠癌患者的II期临床试验

Rechallenge with EGFR inhibitors in ctDNA RAS/BRAF wild type refractory metastatic colorectal cancer: individual patients’ data pooled analysis from 4 phase II trials.

四项Ⅱ期研究的个体患者数据汇总分析：在 ctDNA RAS/BRAF 野生型难治性转移性结直肠癌中使用 EGFR 抑制剂进行再挑战

Randomized phase II trial of durvalumab in combination with olaparib and cediranib (DOC) compared to olaparib and cediranib (OC) or durvalumab and cediranib (DC) or standard of care chemotherapy (SOC) in platinum-resistant ovarian cancer with prior bevacizumab (NRG-GY023)

在既往接受贝伐珠单抗治疗的铂耐药卵巢癌患者中，比较度伐利尤单抗+奥拉帕利+西地尼布（DOC） vs. 奥拉帕利+西地尼布（OC）或度伐利尤单抗+西地尼布（DC）或标准化疗（SOC）的随机Ⅱ期试验（NRG-GY023）

First results from the ENGOT-GYN2/GOG-3051/BOUQUET phase 2 biomarker-directed platform study: cobimetinib (cobi) or atezolizumab (atezo) + bevacizumab (bev) for persistent/recurrent rare epithelial ovarian cancer (eOC)

ENGOT-GYN2/GOG-3051/BOUQUET Ⅱ期生物标志物导向平台研究的首次结果：cobimetinib（cobi）或阿替利珠单抗（atezo）+贝伐珠单抗（bev）治疗持续性/复发性罕见上皮性卵巢癌（eOC）

Efficacy and safety of QL1706 plus paclitaxel and cisplatin/carboplatin +/- bevacizumab (Bev) as 1L treatment in recurrent or metastatic cervical cancer (r/mCC): a single-arm, multicenter phase II study

QL1706 +紫杉醇+顺铂/卡铂±贝伐珠单抗（Bev）作为复发或转移性宫颈癌（r/mCC）1L治疗的疗效和安全性：一项单臂、多中心Ⅱ期研究

AdvanTIG-202: Phase 2 Randomized, Multicenter, Open-Label Study of Tislelizumab (TIS) With or Without Ociperlimab (OCI) in Patients (pts) With Previously Treated Recurrent/Metastatic (R/M) Cervical Cancer (CC)

AdvanTIG-202：替雷利珠单抗（TIS）± ociperlimab（OCI）治疗既往经治的复发/转移性（R/M）宫颈癌（CC）的Ⅱ期随机、多中心、开放研究

Dostarlimab + chemotherapy for the treatment of primary advanced or recurrent endometrial cancer (pA/rEC): analysis of progression free survival (PFS) and overall survival (OS) outcomes by molecular classification in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial

多塔利单抗+化疗治疗原发性晚期或复发性子宫内膜癌（pA/rEC）：ENGOT-EN6-NSGO/GOG-3031/RUBY试验中根据分子分型分析的无进展生存期（PFS）和总生存期（OS）结果

Luveltamab Tazevibulin(STRO-002),an anti-Folate Receptor Alpha(FolRα) Antibody Drug Conjugate(ADC),Demonstrates Clinical Activity in Recurrent/Progressive Epithelial Endometrial Cancer(EEC):STRO-002-GM1 Phase 1 Dose Expansion.

抗叶酸受体α（FolRα）抗体药物偶联物（ADC） Luveltamab Tazevibulin（STRO-002）在复发/进展性上皮性子宫内膜癌（EEC）中显示临床活性：STRO-002-gm1期剂量扩大

会议网址：

https://cslide.ctimeetingtech.com/esmo2023/attendee/confcal/session